Industry Roundup: Zantac 150 Choices, Nature's Health Warning
This article was originally published in The Tan Sheet
Executive Summary
More Zantac 150 choices; Nature's Health warned on claims, GMPs; Marine Ingredients adds Swiss Caps plant; and more news in brief.
You may also be interested in...
Sanofi Looks To Climb Consumer Ladder In Boehringer Business Swap
A pending agreement includes a $5.2bn cash payment from Boehringer to Sanofi but excludes Boehringer’s consumer product business in China. The brands Sanofi will add to its consumer health lineup include two marketed in the US, Dulcolax constipation relief and Zantac heartburn remedy.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.